The Sol Goldman Pancreatic Cancer Research Center, Departments of Pathology and Oncology, the Johns Hopkins University School of Medicine, Baltimore, 21287, MD, USA.
The Department of Pathology, Memorial Sloan Kettering Cancer Center, NY, USA.
Hum Pathol. 2020 Jan;95:99-112. doi: 10.1016/j.humpath.2019.08.024. Epub 2019 Sep 12.
The last 50 years have witnessed an explosion in our understanding of the pathology of pancreatic diseases. Entities known to exist 50 years ago have been defined more precisely and are now better classified. New entities, previously not recognized, have been discovered and can now be treated. Importantly, new tools have been developed that have unraveled the fundamental biological drivers of a number of pancreatic diseases. Many of these same tools have also been applied clinically, supplementing the tried and true hematoxylin and eosin stained slide with a plethora of new, highly sensitive and specific tests that improve diagnostic accuracy and delineate best treatments. As exciting as these many advances are, our knowledge of pancreatic pathology remains incomplete, and there is much to be learned.
过去的 50 年见证了我们对胰腺疾病病理学认识的爆炸式增长。50 年前已知的实体已经被更精确地定义，并且现在可以更好地分类。以前未被认识到的新实体已经被发现，可以进行治疗。重要的是，新的工具已经被开发出来，揭示了许多胰腺疾病的基本生物学驱动因素。许多相同的工具也已经应用于临床，用大量新的、高度敏感和特异的测试来补充久经考验的苏木精和伊红染色载玻片，这些测试提高了诊断的准确性，并确定了最佳的治疗方法。尽管这些许多进展令人兴奋，但我们对胰腺病理学的认识仍然不完整，还有很多需要学习。
